JP2024522389A - 抗体薬物複合体の調製方法および使用 - Google Patents

抗体薬物複合体の調製方法および使用 Download PDF

Info

Publication number
JP2024522389A
JP2024522389A JP2023566660A JP2023566660A JP2024522389A JP 2024522389 A JP2024522389 A JP 2024522389A JP 2023566660 A JP2023566660 A JP 2023566660A JP 2023566660 A JP2023566660 A JP 2023566660A JP 2024522389 A JP2024522389 A JP 2024522389A
Authority
JP
Japan
Prior art keywords
optionally substituted
atoms
group
pharma
meso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566660A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022228495A5 (https=
JP2024522389A5 (https=
Inventor
チャン、ホイ
メン、シュン
Original Assignee
ハイスリンク セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハイスリンク セラピューティクス filed Critical ハイスリンク セラピューティクス
Publication of JP2024522389A publication Critical patent/JP2024522389A/ja
Publication of JPWO2022228495A5 publication Critical patent/JPWO2022228495A5/ja
Publication of JP2024522389A5 publication Critical patent/JP2024522389A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023566660A 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用 Pending JP2024522389A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110475315 2021-04-29
CN202110475315.1 2021-04-29
PCT/CN2022/089726 WO2022228495A1 (zh) 2021-04-29 2022-04-28 抗体偶联药物的制备方法及应用

Publications (3)

Publication Number Publication Date
JP2024522389A true JP2024522389A (ja) 2024-06-19
JPWO2022228495A5 JPWO2022228495A5 (https=) 2025-04-16
JP2024522389A5 JP2024522389A5 (https=) 2025-04-16

Family

ID=83846703

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023566660A Pending JP2024522389A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用
JP2023566547A Pending JP2024522312A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用
JP2023566659A Pending JP2024522388A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023566547A Pending JP2024522312A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用
JP2023566659A Pending JP2024522388A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用

Country Status (10)

Country Link
US (3) US20240238440A1 (https=)
EP (3) EP4331612A1 (https=)
JP (3) JP2024522389A (https=)
KR (2) KR20240006029A (https=)
CN (3) CN117241834A (https=)
AU (1) AU2022263700A1 (https=)
CA (3) CA3173902A1 (https=)
IL (1) IL308025A (https=)
TW (3) TW202308700A (https=)
WO (3) WO2022228494A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024522312A (ja) * 2021-04-29 2024-06-14 ハイスリンク セラピューティクス 抗体薬物複合体の調製方法および使用

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319963A (en) 2022-10-19 2025-05-01 Multitude Therapeutics Inc Antibodies, antibody-drug conjugates, compositions and uses thereof
CN120417935A (zh) * 2022-10-25 2025-08-01 默沙东有限责任公司 依喜替康衍生的adc接头-载荷及其药物组合物和用途
CN120882431A (zh) * 2023-01-11 2025-10-31 金麦安博股份有限公司 接头、药物接头及其缀合物和使用它们的方法
CN118684724A (zh) * 2023-03-22 2024-09-24 映恩生物制药（苏州）有限公司 连接子及其在配体药物偶联物中的应用
TW202438069A (zh) * 2023-03-30 2024-10-01 大陸商上海齊魯製藥研究中心有限公司 依喜替康衍生物及其抗體藥物偶聯物
WO2024212922A1 (zh) * 2023-04-11 2024-10-17 映恩生物制药（苏州）有限公司 喜树碱类化合物及其偶联物、其制备方法和用途
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
CN119300868B (zh) * 2023-05-11 2026-03-13 映恩生物科技(上海)有限公司 喜树碱类化合物及其偶联物、其制备方法和用途
EP4713020A2 (en) * 2023-05-19 2026-03-25 Solve Therapeutics, Inc. Drug-linkers and drug conjugates
CN121772941A (zh) * 2023-06-07 2026-03-31 维申医药(南通)有限公司 一种抗体药物偶联物，及其药物组合物、制备和用途
WO2025005240A1 (ja) * 2023-06-30 2025-01-02 第一三共株式会社 活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法
AU2024288808A1 (en) 2023-07-07 2026-01-22 Shanghai Escugen Biotechnology Co., Ltd. Linker-drug molecule and antibody drug conjugate, preparation method therefor and use thereof
IL326233A (en) * 2023-08-04 2026-03-01 Shanghai Huao Co Ltd Multidrug Linker and Antibody-Drug Conjugation
CN120641100A (zh) * 2023-09-22 2025-09-12 台湾浩鼎生技股份有限公司 用于抗体耦合的改良型连接符-负载物、医药组合物、及其应用
TW202525860A (zh) * 2023-10-23 2025-07-01 大陸商上海齊魯製藥研究中心有限公司 喜樹鹼類藥物耦合物及其製備方法和應用
EP4566631A1 (en) * 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof
WO2025149019A1 (en) * 2024-01-12 2025-07-17 Shanghai Ruotuo Biosciences Co., Ltd. Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications
WO2025153092A1 (en) * 2024-01-18 2025-07-24 Beijing Joinn Biologics Co., Ltd Antibody-drug conjugate
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025209545A1 (zh) * 2024-04-03 2025-10-09 上海药明合联生物技术有限公司 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物
WO2025222052A2 (en) * 2024-04-18 2025-10-23 Solve Therapeutics, Inc. Conjugates and uses thereof
WO2025259928A1 (en) * 2024-06-13 2025-12-18 Obi Pharma, Inc. Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof
WO2025261478A1 (en) * 2024-06-21 2025-12-26 Biotheus Inc. Antibody drug conjugates and applications thereof
WO2026039642A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof
WO2026037394A1 (zh) * 2024-08-16 2026-02-19 石药集团巨石生物制药有限公司 一种抗体药物偶联物及其用途
WO2026046186A1 (en) * 2024-08-27 2026-03-05 Suzhou Bioreinno Biotechnology Limited Company Linkers, linker conjugates and conjugate compounds thereof
WO2026067624A1 (zh) * 2024-09-27 2026-04-02 上海森辉医药有限公司 一种包含亲水基团的配体-药物偶联物及其在医药上的应用
CN119143876B (zh) * 2024-10-09 2025-09-16 武汉海沙百得生物技术有限公司 一种抗cd27l的全人源抗体或抗体片段及其应用
WO2026078443A1 (en) 2024-10-11 2026-04-16 Pheon Therapeutics Ltd. Antibody drug conjugates that bind cdcp1 and uses thereof
CN120484249B (zh) * 2025-04-29 2026-03-10 中山大学 一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015098099A1 (ja) * 2013-12-25 2015-07-02 第一三共株式会社 抗ｔｒｏｐ２抗体－薬物コンジュゲート
WO2018086239A1 (zh) * 2016-11-14 2018-05-17 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
JP2021500412A (ja) * 2017-10-23 2021-01-07 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド−薬物−複合体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
DE60235287D1 (de) * 2001-11-14 2010-03-25 Univ Rutgers Löslich gemachte topoisomerase-gifte
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
RU2015129800A (ru) * 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
RU2019115089A (ru) 2013-04-16 2019-06-11 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
WO2014177042A1 (zh) * 2013-04-28 2014-11-06 Qin Gang 一种新型的连接子及其制备方法和用途
AU2015252518B2 (en) * 2014-04-29 2019-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. New stable antibody-drug conjugate, preparation method therefor, and use thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP4180455A1 (en) 2015-06-29 2023-05-17 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
US10675357B2 (en) 2015-09-09 2020-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to nectin-4 and uses thereof
TW202532102A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物及其用途
KR20220010527A (ko) * 2019-05-20 2022-01-25 노파르티스 아게 친수성 기를 포함하는 링커를 갖는 항체 약물 콘쥬게이트
JP7167163B2 (ja) 2019-05-20 2022-11-08 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 抗体－薬物コンジュゲートの中間体のワンポット合成法による製造プロセス
CN117241834A (zh) * 2021-04-29 2023-12-15 上海汇连生物医药有限公司 抗体偶联药物的制备方法及应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015098099A1 (ja) * 2013-12-25 2015-07-02 第一三共株式会社 抗ｔｒｏｐ２抗体－薬物コンジュゲート
WO2018086239A1 (zh) * 2016-11-14 2018-05-17 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
JP2021500412A (ja) * 2017-10-23 2021-01-07 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド−薬物−複合体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Antibody-drug conjugates: Recent advances in linker chemistry", ACTA PHARM SIN B, vol. (Epub 2021 Apr 6);11(12), JPN6026003813, 2021, pages 3889 - 3907, ISSN: 0005785065 *
CHEM. SCI., vol. 10, JPN6026003815, 2019, pages 4048 - 4053, ISSN: 0005785063 *
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 167, JPN6026003816, 2019, pages 583 - 593, ISSN: 0005785062 *
PHARMACEUTICALS, vol. 14,247, JPN6026003814, March 2021 (2021-03-01), ISSN: 0005785064 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024522312A (ja) * 2021-04-29 2024-06-14 ハイスリンク セラピューティクス 抗体薬物複合体の調製方法および使用

Also Published As

Publication number Publication date
CN117241833A (zh) 2023-12-15
IL308025A (en) 2023-12-01
US20240245799A1 (en) 2024-07-25
EP4331611A1 (en) 2024-03-06
WO2022228495A1 (zh) 2022-11-03
WO2022228494A1 (zh) 2022-11-03
CA3173511A1 (en) 2023-10-28
EP4331613A1 (en) 2024-03-06
KR20240006028A (ko) 2024-01-12
WO2022228493A1 (zh) 2022-11-03
CA3173758A1 (en) 2022-11-03
JP2024522312A (ja) 2024-06-14
US20240238440A1 (en) 2024-07-18
CA3173902A1 (en) 2022-11-03
CN117337195A (zh) 2024-01-02
TW202308701A (zh) 2023-03-01
CN117241834A (zh) 2023-12-15
AU2022263700A1 (en) 2023-11-16
KR20240006029A (ko) 2024-01-12
TW202309045A (zh) 2023-03-01
US20240245795A1 (en) 2024-07-25
EP4331612A1 (en) 2024-03-06
JP2024522388A (ja) 2024-06-19
TW202308700A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
JP2024522389A (ja) 抗体薬物複合体の調製方法および使用
CN108101825B (zh) 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途
JP7390000B2 (ja) 抗体－ポリマー－薬物コンジュゲート
JP2023520930A (ja) 電荷多様性リンカー
TW202448955A (zh) B7h4抗體藥物偶聯物及其用途
JP7203834B2 (ja) イムノコンジュゲートにおけるメチオニン酸化を防止する方法
KR20240022626A (ko) 항종양 화합물 및이의 응용
JP2024528719A (ja) コンジュゲート化試薬及びそのコンジュゲート
JP2022500454A (ja) 抗葉酸受容体抗体コンジュゲートによる併用療法
RU2803119C2 (ru) Способы предотвращения окисления метионина в иммуноконъюгатах
JP2025123209A (ja) 新薬物複合体
WO2024034684A1 (ja) 新薬物複合体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260130